LCGC UST
Feature|Videos|September 30, 2024

The Regulatory Stance on Oligonucleotide Enantiomers

Author(s)LCGC Editors

The panel dives into the regulatory stance on oligonucleotide enantiomers. The role of batch-to-batch reproducibility, new drug application (NDA) filing, and current guidelines are covered.

Regulatory guidelines must be considered when discussing oligonucleotide analysis and enantiomers. The panel reviews the current regulatory stance on this topic and common analytical bottlenecks relative to regulatory compliance.

Related to this article

Best of the Week: From Olive Waste to mRNA Vaccines
This week's Chromatography Online highlights include olive waste antioxidant recovery, food and tea analysis, EV isolation, mRNA vaccine purification, perfusion chromatography for oligonucleotides, mass spectrometry in teaching and career advice from “Women in Chromatography.”